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Javier Rojoa
α(1,2)mannobiosides with diﬀerent substituents at the reducing end have been synthesized by a common
strategy using benzoyls as the permanent protecting groups and an acetyl as the orthogonal protecting
group at position C2 of the glycosyl acceptor. The new synthetic strategy has been performed remarkably
reducing the number of puriﬁcation steps, the time of synthesis (less than 72 hours) and improving the
overall yield at least three times with respect to the best procedure described in the literature at the
moment. Additionally, this protecting group strategy is compatible with the presence of azido groups and
the use of Cu catalyzed azide alkyne cycloaddition (CuAAC) also called “click chemistry” for conjugating
the α(1–2)mannobiosides to diﬀerent scaﬀolds for the preparation of mannosyl multivalent systems.
Introduction
High-mannose oligosaccharides are ubiquitous biologically
important molecules. They are known to participate in quality
control and intracellular transportation of glycoproteins.1 Fur-
thermore, they are present on the surface of many pathogenic
microorganisms such as viruses, bacteria, fungi and parasites,
and they are the target of immune system cells, including
macrophages and dendritic cells.2 The interactions of high-
mannose oligosaccharides with animal lectins are of crucial
importance for the eﬃcient operation of the innate immune
system. Examples include the mannose-binding lectin (MBL),
Dendritic Cell Specific ICAM-3 Grabbing Non-integrin
(DC-SIGN), defensins and macrophage mannose receptors
(MRs).3 Therefore, the glycan structures on pathogen glyco-
proteins present in viral envelopes or bacterial cell walls help
in escaping recognition by the immune system, and the sub-
sequent elimination or neutralization of the pathogen.2 In par-
ticular, the group of van Kooyk in 2000 highlighted the
relevance of DC-SIGN reporting the role that this lectin plays
in the pathogenesis of HIV-1.4 This virus targets DC-SIGN, but
escapes degradation in lytic compartments, thus using the
DCs as a Trojan Horse to invade the host organism.4 In this
context, inhibition of DC-SIGN is currently considered as an inter-
esting new target for the design of anti-infective agents.5 Infor-
mation at the molecular level concerning the mechanism by
which this receptor operates is scarce, thus eﬀective modulators
of DC-SIGN are also required to clarify the diﬀerent biological
pathways in which this receptor is involved. The main carbo-
hydrate ligand recognized by DC-SIGN is the high mannose
glycan, (Man)9(GlcNAc)2, a branched oligosaccharide containing
mannose with α1,2-, α1,3-, α1,6-, and β1,4-linkages (Fig. 1). Mul-
tiple copies of this glycan are present in several pathogen glyco-
proteins and specifically in the gp120 envelope protein of HIV.
The total synthesis of Man9 or (Man)9(GlcNAc)2 has been
explored for the past two decades;6 however, the complexity of
these kinds of complex glycan structures prevent accessibility
to the large amounts required to address biological studies.
Thus synthetic glycan mimetics can be of great value for inter-
rogating these relevant biological interactions. The crystal
structure of a complex containing a Fab fragment of the gp120
antibody 2G12 and (Man)9(GlcNAc)2 was published more than
Fig. 1 Structure of high-mannose type glycans.
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10 years ago.7 The resolved structure shows that the
Manα1–2Man residues constitute 85% of the protein contacts.
Additionally, it is known that high density arrays of
unbranched Manα(1,2)Man bind to DC-SIGN almost as eﬀec-
tively as the entire Man9 oligosaccharide.
8 Based on this,
Manα1–2Man can be considered as an interesting fragment for
constructing multivalent systems mimicking high-mannose
interactions. For this reason, a rapid and straightforward syn-
thesis of Manα1,2Man disaccharide conveniently functiona-
lized in the reducing end to facilitate their conjugation to
multivalent scaﬀolds is of remarkable interest. The previously
described approaches to prepare α(1–2) mannobioside deriva-
tives involved many reaction steps, including the classical pro-
tection–deprotection pathway to prepare oligosaccharides,
with several purifications of the intermediate products. These
syntheses imply large time consumption, high synthetic cost,
and render a low overall yield of the final product. A recent
example describes an eﬃcient one-step synthesis of α(1–2)
mannobioside using a polymerization-type strategy.9 This
approach provides an excellent overall yield only when the
linker used in the reducing terminus is an alcohol with a par-
ticular length and substituents, implying an important
decrease in the versatility of the synthesis. These disadvan-
tages make the current application of Manα1,2Man diﬃcult
and compromise its use in preparing multivalent glycoconju-
gates with potential anti-infective properties.
Here, we present a very rapid, straightforward, versatile and
high yield synthesis of Manα1,2Man derivatives with –OMe,
2-azidoethyl and S-tolyl functionalization in the reducing end.
To achieve this objective, a common orthogonal protection
strategy was designed employing benzoates as the permanent
protecting groups and an acetate as the orthogonal protecting
group at position C2 of the glycosyl acceptor. The use of this
protecting group strategy is compatible with the presence of
azido groups and the use of CuAAC (Cu catalyzed azide alkyne
cycloaddition) also called “click chemistry” for conjugating the
α(1–2)mannobiosides to diﬀerent scaﬀolds.
Results and discussion
An eﬃcient synthesis of α(1–2)mannobiosides can provide the
required materials to facilitate a gram scale preparation of
multivalent systems opening the door to explore their biologi-
cal applications. The key step for a straightforward synthesis of
these disaccharides is a rapid and eﬃcient strategy to obtain
large amounts of glycosyl donors and acceptors compatible
with the methodology selected for the multivalent presentation
of the final oligosaccharides. With this aim, we selected as gly-
cosyl donors the per-acetylated and per-benzoylated mannose
trichloroacetimidate 13 and 14 (Scheme 3) and as glycosyl
acceptors the mannoside derivatives 11 and 12 (Scheme 1).
Our strategy starts from the methyl and 2-azidoethyl manno-
pyranoside (3 and 4) that were treated with BzCN at −40 °C
and a catalytic amount of Et3N to selectively protect the
C6 hydroxyl group.10 This reaction was regioselective and the
primary alcohols of both mannose derivatives 3 and 4 were
selectively benzoylated with good yield after chromatographic
purification (61% for 5 and 71% for 6), and only a small
amount (less than 10%) of 2,6- and 3,6-benzoyl derivatives
were observed by TLC and verified by NMR spectroscopy. The
monobenzoylation step could be considered one of the key
steps of this synthetic strategy. The regioselective benzoylation
of the primary alcohol using fully deprotected mannose has
not been performed previously. The selective protection of
primary alcohols in the presence of secondary alcohols has
often been addressed by the use of high hindrance protecting
groups such as tert-butyldiphenylsilyl ether (TBDPS).11 In our
strategy, the use of silylethers is incompatible with the de-
protection conditions of the orthogonal acetyl group at posi-
tion C2 of the glycosyl donor.
Then, compounds 5 and 6 were treated with trimethyl
orthoacetate and a catalytic amount of camphorsulphonic acid
(CSA) to form the acetyl orthoester with the hydroxyl groups at
positions C2 and C3. This orthoester was impossible to isolate
due to the partial hydrolysis of the orthoester functionality
during the chromatographic purification. The treatment of the
orthoester intermediates with 1 M HCl implied partial hydro-
lysis to obtain the hydroxyl groups at position C2 orthogonally
protected with an acetate group and with the hydroxyl groups
in C3 and C4 unprotected (7 and 8).12 These compounds were
finally benzoylated with Bz2O, Et3N and a catalytic amount of
4-dimethylaminopyridine (DMAP) to generate the fully protec-
tive mannose derivatives 9 and 10 with an acetyl group as the
orthogonal protecting group at position C2. Finally, selective
deprotection of this acetyl group at position C2 using 7% HCl
in methanol aﬀorded the mannoses 11 and 12 in good
yields.13 The use of 7% HCl in methanol was the best con-
dition found to achieve the compromise of completing the
reaction in less than 24 hours and avoiding the partial hydro-
lysis of benzoyl esters present in the mannose derivatives.
Both intermediates 11 and 12 were used as acceptors for the
synthesis of the α(1,2)mannobiosides (Scheme 3).
This synthetic strategy to prepare mannose acceptors 11
and 12 implied 5 reaction steps and 4 purifications using
silica gel flash chromatography with an overall yield of 42% in
the case of the OMe derivative 11 and 40% for the 2-azidoethyl
Scheme 1 Synthesis of mannose derivatives 11 and 12.
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derivative 12. Many diﬀerent strategies have been described in
the literature to aﬀord these kinds of intermediates, using 1,2-
O-ethylidene-β-D-mannopyranosides and other approaches like
benzyl/acetyl or benzyl/Fmoc strategies.13,14 All these alterna-
tives mean at least the same number of reactions and purifi-
cations steps with an overall yield of 25% in the best case.
It is important to highlight that the synthetic approach
described in Scheme 1 to obtain the glycosyl acceptors 11 and
12 presents an important advantage: the conditions of the pro-
tection reactions are all compatible for being carried out
sequentially simply by the removal of the reaction solvent and
a work up without chromatographic purification of the inter-
mediate products. For these reasons, we aﬀorded the sequence
synthesis of 11 and 12 as described in Scheme 2. The prepa-
ration of intermediates 11 and 12 was performed in only
28 hours with a single final chromatographic purification with
72% and 70% overall yields, respectively. This consecutive
strategy means a 30% increase in the yield over the step-wise tra-
ditional synthetic strategy demonstrating that limiting the
number of purification steps produces an improvement in the
final overall yield. Additionally, the consecutive strategy also intro-
duces a significant reduction of the total cost and time of the syn-
thesis of these key intermediates to achieve the preparation of the
target molecule, the mannobioside. In fact, we have obtained a
decrease of about 80% of the time, allowing the preparation of
these derivatives in the gram scale in less than two days very
easily. Moreover, this versatile approach allows diﬀerent modifi-
cations for generating a large number of mannose monosacchar-
ides, for example, the benzoyl groups could be substituted by
benzyls or other kinds of protecting groups.
At this stage, only the preparation of the glycosyl donors is
necessary to complete the synthesis of the disaccharides.
α-1,2-Linked dimannosides 1 and 2 were synthesized with the
α linkage typically controlled by a participating neighboring
group at the C2 position of the glycosyl donor. Two diﬀerent
glycosyl donors were selected, per-acetylated and per-benzoy-
lated trichloroacetimidates 13 and 14 (Scheme 3). The di-
saccharides 15 and 16 were prepared by reaction of the glycosyl
donor 13 with the glycosyl acceptors 11 and 12 using trimethyl-
silyl triflate (TMSOTf) as the promoter at 0 °C with moderate
yields (46% and 59%, respectively). The moderate yield of these
glycosylations was due to the orthoester formation during the
reaction. In order to avoid this problem and to increase the
yield of the glycosylation step, per-benzoylated mannose 14 was
used as the glycosyl donor.15 Using the same conditions (0.2 eq.
of TMSOTf), disaccharides 17 and 18 were obtained in good
yields (75% and 78%, respectively). Finally, the disaccharides 1
and 2 were prepared by the deprotection of acetyl and benzoyl
groups using classical Zempler conditions (NaOMe/MeOH) to
aﬀord the final compounds 1 and 2 in quantitative yields.
To explore the scope of the methodology described in this
work as a straightforward strategy to address the preparation
of more complex oligosaccharides that present Manα1,2Man
units in their structure, the S-tolyl mannose derivative 21 was
prepared following the consecutive synthetic procedure
described for compounds 11 and 12 and starting from the
S-tolyl derivative 19 (Scheme 4). Compound 20 was prepared
from the S-tolyl derivative 1916 in less than 36 hours with 65%
yield using only one chromatographic purification. Then,
applying the methodology described by Wong and co-
workers,17 compound 20 was used simultaneously as a glycosyl
donor and acceptor to aﬀord self-glycosidation with N-iodo
succinimide (NIS) and triflic acid (TfOH) at −40 °C providing
the dimannoside 21 with 68% yield. The dimannoside 21 is an
excellent synthetic intermediate that could be used as a donor
or acceptor to synthesize more complex oligosaccharides.
Conclusions
In summary, we have completed the consecutive synthesis
of three α(1,2)mannobiosides, the methyl derivative 1, theScheme 2 Consecutive synthetic procedures to prepare 11 and 12.
Scheme 3 Synthetic strategies to prepare the α(1,2)mannobiosides
1 and 2.
Scheme 4 (a) Consecutive synthesis of donor/acceptor 20; (b) self-gly-
cosidation of 20 to obtain the disaccharide 21.
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2-azidoethyl derivative 2 and the S-tolyl derivative 21. The
preparation of these molecules has been achieved using a
common strategy based on benzoyls as the permanent protecting
groups and an acetyl as the orthogonal protecting group at the
C2 position of the glycosyl acceptor. Following this strategy,
the purification steps have been reduced to only two silica gel
column chromatographies for every disaccharide, minimizing
the time spent to perform the synthesis of these final
compounds to less than 72 hours and improving the overall
yield at least three times with respect to the best procedure
described in the literature. This synthetic strategy allows the
preparation of α(1,2)dimannosides in the gram scale reducing
the cost of the synthesis a lot. Additionally, the use of the ester
strategy (benzoyl/acetyl) makes the synthesis compatible with
the 2-azidoethyl spacer in the case of compound 2. This is
fundamental for the preparation of glycoconjugates by click
chemistry reactions using multivalent scaﬀolds. On the
basis of this development, we are preparing multivalent
Manα1,2Man conjugates using compound 1 as the ligand and
we are synthesizing more complex mannose oligosaccharides
using the S-tolyl 21 derivative as the synthetic intermediate.
Experimental
Materials and methods
All chemicals were obtained from Sigma-Aldrich and used
without further purification, unless otherwise noted. 1H and
13C NMR were recorded on Bruker Advance DPX 300 and DRX
400 MHz spectrometers. Chemical shifts are in ppm with
respect to tetramethylsilane (TMS) using the manufacturer’s
indirect referencing method. 2D experiments (COSY
and HSQC) were performed when necessary to assign the
oligosaccharide spectra. Mass spectra were recorded with an
Esquire 6000 ESI-Ion Trap from Bruker Daltonics.
Synthetic procedures
Synthesis of methyl-6-O-benzoyl-α-D-mannopyranoside
(5). To a solution of methyl-α-D-mannopyranoside (3) (300 mg,
1.55 mmol) in DMF (10 mL) at −40 °C were added dropwise a
solution of BzCN 1 M in DMF (2 mL) and a catalytic amount of
Et3N and the reaction was stirred for 2 hours. After that,
MeOH (4 mL) was added to quench excess BzCN and the reac-
tion was warmed up to room temperature. Then, the solvent
was evaporated and the residue was purified by flash chrom-
atography on silica gel (CH2Cl2 : MeOH, 40 : 1) to give com-
pound 5 as a colorless oil (280 mg, 61%). 1H NMR (400 MHz,
CDCl3) δ 8.09 (dd, J = 8.4, 1.3 Hz, 2H, 2HBz), 7.60 (tt, J = 7.6, 1.3
Hz, 1H, 1HBz), 7.47 (dd, J = 8.4, 1.3 Hz, 2H, 2HBz), 4.82 (dd, J =
12.2, 4.8 Hz, 1H, H6Man), 4.79 (d, J = 1.5 Hz, 1H, H1Man), 4.54
(dd, J = 12.1, 2.2 Hz, 1H, H6Man), 3.99 (dd, J = 3.4, 1.6 Hz, 1H,
H2Man), 3.89 (dd, J = 9.1, 3.3 Hz, 1H, H3Man), 3.87–3.83 (m, 1H,
H5Man), 3.73 (t, J = 9.5 Hz, 1H, H4Man), 3.42 (s, 3H, –OCH3).
13C
NMR (101 MHz, CDCl3) δ 167.2 (CvOBz), 133.2 (CHBz), 129.7
(CHBz), 128.4 (CHBz), 100.9 (C1Man), 71.6 (C5Man), 70.6 (C3Man),
70.5 (C2Man), 67.9 (C4Man), 64.6 (C6Man), 54.9 (OCH3). ESI-MS
for C14H18O7; calcd: 298.1 M
+; found: 321.2 [M + Na]+;
ESI-HRMS for C14H18O7; calcd: 321.0950 [M + Na]
+; found:
321.0943 [M + Na]+.
Synthesis of 2-azidoethyl-6-O-benzoyl-α-D-mannopyranoside
(6). To a solution of 2-azidoethyl-α-D-mannopyranose (4)
(100 mg, 0.40 mmol) in DMF (4 mL) at −40 °C were added a
solution of BzCN 1 M in DMF (480 μL) and a catalytic amount
of Et3N and the reaction was stirred for 2 hours. After that,
MeOH (1 mL) was added to quench excess BzCN and the reac-
tion was warmed up to room temperature. Then, the solvent
was evaporated and the residue was purified by flash chrom-
atography on silica gel (CH2Cl2 : MeOH, 20 : 1) to give com-
pound 6 as a colorless oil (99 mg, 71%). 1H NMR (400 MHz,
CDCl3) δ 8.06 (d, J = 8.2 Hz, 2H, 2HBz), 7.58 (t, J = 7.8 Hz, HBz),
7.44 (t, J = 7.7 Hz, 2HBz), 4.91(d, J = 1.6 Hz, 1H, H1Man) 4.75
(ddd, J = 12.2, 5.8, 2.9 Hz, 1H, H6Man), 4.58 (dt, J = 12.2, 1.8 Hz,
1H, H6Man), 4.04 (dd, J = 3.4, 1.6 Hz, 1H, H2Man), 3.97–3.84 (m,
3H, H3Man + H5Man + H7) 3.80 (t, J = 9.4 Hz, 1H, H4Man),
3.67–3.59 (m, 1H, H7), 3.45–3.34 (m, 2H, 2H8).
13C NMR
(101 MHz, CDCl3) δ 167.1 (CvOBz), 133.2 (CBz), 129.7 (CHBz),
128.4 (CHBz), 100.0 (C1Man), 71.4 (C3Man or C5Man), 71.0 (C3Man
or C5Man), 70.5 (C2Man), 67.8 (C4Man), 66.5(C7), 64.6 (C6Man),
50.4 (C8). ESI-MS for C15H19N3O7; calcd: 353.1 M
+; found:
376.2 [M + Na]+; ESI-HRMS for C15H19N3O7; calcd: 376.1121
[M + Na]+; found: 376.1113 [M + Na]+.
Synthesis of methyl-2-O-acetyl-6-O-benzoyl-α-D-mannopyra-
noside (7). To a solution of methyl-6-O-benzoyl-α-D-mannopyr-
anoside (5) (220 mg, 0.74 mmol) and CSA (35 mg, 0.15 mmol)
in CH3CN (7 mL) was added trimethyl orthoacetate (285 μL,
2.22 mmol) and the reaction was stirred at room temperature
for 1 hour. After that, the reaction was quenched with Et3N
(100 μL) and the solvent was evaporated. Then, the residue was
dissolved in EtOAc (25 mL) and washed with 1 M HCl (25 mL),
the organic phase was dried with anh. MgSO4 and the solvent
was evaporated. Finally, the residue was purified by flash
chromatography on silica gel (CH2Cl2 : MeOH, 50 : 1) to give
compound 7 as a colorless oil (215 mg, 85%). 1H NMR
(400 MHz, CDCl3) δ 8.11 (d, J = 7.6 Hz, 2H, 2HBz), 7.62 (t, J =
7.4 Hz, 1H, HBz), 7.48 (t, J = 7.6 Hz, 1H, 2HBz), 5.13 (dd, J = 3.5,
1.6 Hz, 1H, H2Man), 4.81 (dd, J = 12.2, 4.6 Hz, 1H, H6Man), 4.78
(d, J = 1.6 Hz, 1H, H1Man), 4.56 (dd, J = 12.3, 2.1 Hz, 1H,
H6Man), 4.08 (dd, J = 9.7, 3.4 Hz, 1H, H3Man), 3.96 (m, 1H,
H5Man), 3.77 (t, J = 9.6 Hz, 1H, H4Man), 3.43 (s, 3H, OCH3), 2.11
(s, 3H, –OCOCH3).
13C NMR (101 MHz, CDCl3) δ 170.7
(CvOAc), 167.3 (CvOBz), 133.4 (CHBz), 129.8 (CHBz), 129.7
(CBz), 128.4 (CHBz), 98.7 (C1Man), 71.8 (C2Man), 70.6 (C5Man),
69.9 (C5Man), 67.9 (C3Man), 63.8 (C6Man), 55.2 (–OCH3), 20.9
(–OCOC̲H3). ESI-MS for C16H20O8; calcd: 340.1 M
+; found:
363.2 [M + Na]+; ESI-HRMS for C16H20O8; calcd: 363.1056
[M + Na]+; found: 363.1045 [M + Na]+.
Synthesis of 2-azidoethyl-2-O-acetyl-6-O-benzoyl-α-D-manno-
pyranoside (8). To a solution of 2-azidoethyl-6-O-benzoyl-α-D-
mannopyranoside (6) (80 mg, 0.23 mmol) and CSA (5 mg,
0.02 mmol) in CH3CN (4 mL) was added trimethyl orthoacetate
(86 mL, 0.68 mmol) and the reaction was stirred at room temp-
erature for 1 hour. After that, the reaction was quenched with
Paper Organic & Biomolecular Chemistry
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Et3N (50 μL) and the solvent was evaporated. Then, the residue
was dissolved in EtOAc (25 mL) and washed with 1 M HCl
(25 mL), the organic phase was dried with anh. MgSO4 and the
solvent was evaporated. Finally, the residue was purified by
flash chromatography on silica gel (CH2Cl2 : MeOH, 100 : 3) to
give compound 8 as a colorless oil (63 mg, 70%). 1H NMR
(400 MHz, CDCl3) δ 8.10 (dd, J = 8.3, 1.4 Hz, 2H, 2HBz), 7.61 (t,
J = 7.2 Hz, 1H, HBz), 7.47 (t, J = 7.6 Hz, 1H, 2HBz), 5.16 (dd, J =
3.5, 1.6 Hz, 1H, H2Man), 4.91 (d, J = 1.6 Hz, 1H, H1Man), 4.78
(dd, J = 12.1, 4.7 Hz, 1H, H6Man), 4.59 (dd, J = 12.2, 2.2 Hz, 1H,
H6Man), 4.12 (dd, J = 9.5, 3.5 Hz, 1H, H3Man), 3.96 (ddd, J = 9.9,
4.7, 2.2 Hz, 1H, H5Man), 3.91 (ddd, J = 10.6, 7.0, 3.6 Hz, 1H,
H7), 3.82 (t, J = 9.7 Hz, 1H, H4Man), 3.66 (ddd, J = 10.5, 6.0, 3.4
Hz, 1H, H7), 3.44 (qdd, J = 13.3, 6.5, 3.5 Hz, 2H, 2H8), 2.11 (s,
3H, –OCOCH3).
13C NMR (101 MHz, CDCl3) δ 170.8 (CvOAc),
167.1 (CvOBz), 133.4 (CHBz), 129.8 (CHBz), 129.7 (CBz), 128.5
(CHBz), 97.8 (C1Man), 76.7 (C2Man), 71.7 (C2Man), 71.1 (C5Man),
69.6 (C3Man), 67.7 (C4Man), 66.8 (C7), 63.8 (C6Man), 50.5 (C8),
20.9 (–OCOC̲H3). ESI-MS for C17H21N3O8; calcd: 395.1 M
+;
found: 418.2 [M + Na]+; ESI-HRMS for C17H21N3O8; calcd:
418.1226 [M + Na]+; found: 418.1219 [M + Na]+.
Synthesis of methyl-2-O-acetyl-3,4,6-tri-O-benzoyl-α-D-
mannopyranoside (9). To a solution of methyl-6-O-benzoyl-α-D-
mannopyranoside (7) (177 mg, 0.52 mmol) in CH2Cl2 (10 mL)
were subsequently added Bz2O (350 mg, 1.56 mmol), Et3N
(220 μL, 1.56 mmol) and 4-dimethylaminopyridine (4-DMAP)
(7 mg, 0.01 mmol) and the reaction was stirred at room temp-
erature for 1 hour. Then, the solvent was evaporated and the
residue was dissolved in EtOAc (25 mL). The solution was
washed with 1 M HCl (25 mL), sat. NaHCO3 (25 mL) and water
(25 mL), the organic phase was dried over anh. MgSO4 and the
solvent was evaporated. Finally, the residue was purified by
flash chromatography on silica gel (hexane : EtOAc, 2 : 1) to
give compound 9 as a colorless oil (255 mg, 90%). 1H NMR
(400 MHz, CDCl3) δ 8.08 (d, J = 7.5, 2H, 2HBz), 7.97 (d, J = 7.5
Hz, 1H, 2HBz), 7.91 (d, J = 7.5, 2H, 2HBz), 7.60–7.29 (m, 9H,
9HBz), 5.92 (t, J = 10.0 Hz, 1H, H4Man), 5.81 (dd, J = 10.0, 3.2
Hz, 1H, H3Man), 5.52 (dd, J = 3.2, 1.6 Hz, 1H, H2Man), 4.88 (d,
J = 1.6 Hz, 1H, H1Man), 4.65 (dd, J = 12.2, 3.0 Hz, 1H, H6Man),
4.52 (dd, J = 12.0, 5.2 Hz, 1H, H6Man), 4.41–4.37 (m, 1H,
H5Man), 3.53 (s, 3H, –OCH3), 2.17 (s, 3H, –OCOCH3).
13C NMR
(75 MHz, CDCl3) δ 169.9 (CvOAc), 166.2 (CvOBz), 165.6
(CvOBz), 165.4 (CvOBz), 133.5 (CvOBz), 133.2(CHBz), 133.1
(CHBz), 129.8 (CHBz), 129.7 (CHBz), 129.2 (CBz), 129.0, (CHBz)
128.5 (CHBz), 128.4 (CHBz), 98.6 (C1Man), 69.9 (C2Man), 69.8
(C3Man), 68.7 (C5Man), 67.1 (C4Man), 63.4 (C6Man), 50.5 (–OCH3),
20.8 (–OCOC̲H3). ESI-MS for C30H28O10; calcd: 548.2 M
+;
found: 571.3 [M + Na]+; ESI-HRMS for C30H28O10; calcd:
571.1780 [M + Na]+; found: 571.1771 [M + Na]+.
Synthesis of 2-azidoethyl-2-O-acetyl-3,4,6-tri-O-benzoyl-α-D-
mannopyranoside (10). To a solution of 2-azidoethyl-6-O-
benzoyl-α-D-mannopyranoside (8) (60 mg, 0.15 mmol) in
CH2Cl2 (4 mL) were subsequently added Bz2O (138 mg,
0.61 mmol), Et3N (85 μL, 0.61 mmol) and 4-DMAP (3 mg,
0.02 mmol) and the reaction was stirred at room temperature
for 1 hour. Then, the solvent was evaporated and the residue
was dissolved in EtOAc (20 mL). The solution was washed with
1 M HCl (20 mL), sat. NaHCO3 (20 mL) and water, the organic
phase was dried over anh. MgSO4 and the solvent was evapor-
ated. Finally, the residue was purified by flash chromatography
on silica gel (hexane : EtOAc, 2 : 1) to give compound 10 as a
colorless oil (81 mg, 90%). 1H NMR (300 MHz, CDCl3) δ 8.08
(d, J = 7.5, 2H, 2HBz), 7.97 (dd, J = 8.3, 1.4 Hz, 1H, 2HBz), 7.92
(d, J = 7.5, 2H, 2HBz), 7.69–7.31 (m, 9H, 9HBz), 5.96 (t, J = 9.9
Hz, 1H, H4Man), 5.83 (dd, J = 10.1, 3.3 Hz, 1H, H3Man), 5.52 (dd,
J = 3.3, 1.8 Hz, 1H, H2Man), 5.02 (d, J = 2.0 Hz, 1H, H1Man), 4.65
(dd, J = 12.0, 2.4 Hz, 1H, H6Man), 4.60–4.39 (m, 2H, H5Man +
H6Man), 3.99 (ddd, J = 10.7, 7.2, 3.6 Hz, 1H, H7), 3.75 (ddd, J =
10.2, 5.9, 3.5 Hz, 1H, H7), 3.58 (ddd, J = 9.8, 6.5, 2.9 Hz, 1H,
H8), 3.47 (ddd, J = 9.8, 6.5, 2.9 Hz, 1H, H8), 2.14 (s, 3H,
–OCOCH3).
13C NMR (75 MHz, CDCl3) δ 169.8 (CvOAc), 166.0
(CvOBz), 165.4 (CvOBz), 165.3 (CvOBz), 133.4 (CHBz), 133.2
(CHBz), 133.0 (CHBz), 129.8 (CHBz), 129.7 (CBz), 129.7 (CHBz),
129.6 (CHBz), 129.6 (CHBz), 129.5 (CBz), 129.0 (CBz), 128.8
(CHBz), 128.4 (CHBz), 128.3 (CHBz), 128.2 (CHBz), 97.5 (C1Man),
69.7 (C2Man), 69.5 (C4Man), 69.1 (C5Man), 67.1 (C7), 66.8 (C3Man),
63.1 (C6Man), 50.3 (C8), 20.7 (–OCOC̲H3). ESI-MS for
C31H29N3O10; calcd: 603.2 M
+; found: 626.2 [M + Na]+;
ESI-HRMS for C31H29N3O10; calcd: 626.1751 [M + Na]
+; found:
626.1740 [M + Na]+.
Synthesis of methyl-3,4,6-tri-O-benzoyl-α-D-mannopyrano-
side (11). To a solution of methyl-2-O-acetyl-3,4,6-tri-O-
benzoyl-α-D-mannopyranoside (9) (244 mg, 0.445 mmol) in
CH3CN (5 mL) was added a solution of 7% HCl in MeOH
(10 mL) and the reaction was stirred at room temperature for
24 hours. Then, the solvent was evaporated and the residue
was dissolved in EtOAc (25 mL). The solution was washed with
a solution of sat. NaHCO3 (2 × 50 mL) and water (50 mL). The
organic phase was dried over anh. MgSO4 and the solvent was
evaporated to obtain compound 11 as a colorless oil (200 mg,
89%). 1H NMR (400 MHz, CDCl3) δ 8.06 (d, J = 6.9 Hz, 1H,
2HBz), 8.00 (d, J = 8.3, 1.6 Hz, 1H, 2HBz), 7.97 (d, J = 8.3, 1.6
Hz, 1H, 2HBz), 7.63–7.47 (m, 2H, 3 HBz), 7.48–7.34 (m, 6H,
6HBz), 5.96 (t, J = 10.0 Hz, 1H, H4Man), 5.70 (dd, J = 10.0, 3.1
Hz, 1H, H3Man), 4.92 (d, J = 1.8 Hz, 1H, H1Man), 4.63 (dd, J =
12.0, 3.0 Hz, 1H, H6Man), 4.52 (dd, J = 12.0, 5.5 Hz, 1H, H6Man),
4.42–4.33 (m, 1H, H2Man + H5Man), 3.54 (s, 3H, –OCH3), 2.26 (d,
J = 4.7 Hz, 1H, –OH). 13C NMR (101 MHz, CDCl3) δ 166.2
(CvOBz), 165.6 (CvOBz), 165.5 (CvOBz), 133.4 (CHBz), 133.3
(CHBz), 133.1 (CHBz), 129.8 (CHBz), 129.8 (CHBz), 129.7 (CHBz),
129.2 (CHBz), 129.1 (CHBz), 128.4 (CHBz), 128.4 (CHBz), 128.3
(CHBz), 100.7 (C1Man), 72.6 (C3Man), 69.41 (C2Man or C5Man),
68.6 (C2Man or C5Man), 67.0 (C4Man), 63.6 (C6Man), 55.38
(C-OCH3). ESI-MS for C28H26O9; calcd: 506.2 M
+; found: 529.3
[M + Na]+; ESI-HRMS for C28H26O9; calcd: 529.1469 [M + Na]
+;
found: 529.1452 [M + Na]+.
Synthesis of 2-azidoethyl-3,4,6-tri-O-benzoyl-α-D-mannopyra-
noside (12). To a solution of 2-azidoethyl-2-O-acetyl-3,4,6-tri-O-
benzoyl-α-D-mannopyranoside (10) (64 mg, 0.114 mmol) in
CH3CN (1 mL) was added a solution of 7% HCl in MeOH (2 mL)
and the reaction was stirred at room temperature for 24 hours.
Then the solvent was evaporated and the residue was dissolved
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in EtOAc (25 mL). The solution was washed with a solution of
sat. NaHCO3 (2 × 25 mL) and water (25 mL). The organic phase
was dried over anh. MgSO4 and the solvent was evaporated to
obtain compound 12 as a colorless oil (49 mg, 90%). 1H NMR
(300 MHz, CDCl3) δ 8.03 (d, J = 6.9 Hz, 1H, 2HBz), 7.97 (d, J =
7.0 Hz, 2H, 2HBz), 7.94 (d, J = 7.0 Hz, 2H, 2HBz), 5.98 (t, J = 10.0
Hz, 1H, H4Man), 5.71 (dd, J = 10.0, 3.1 Hz, 1H, H3Man), 5.04 (d,
J = 1.9 Hz, 1H, H1Man), 4.60 (dd, J = 12.0, 3.1 Hz, 1H, H6Man),
4.52 (dd, J = 12.0, 5.2 Hz, 1H, H6Man), 4.47–4.33 (m, 2H, H2Man +
H4Man), 4.00 (ddd, J = 10.4, 6.2, 3.9 Hz, 1H, H7), 3.74 (ddd, J =
10.4, 6.0, 3.7 Hz, 1H, H7), 3.61–3.39 (m, 2H, H8).
13C NMR
(75 MHz, CDCl3) δ 166.6 (CvOBz), 166.0 (CvOBz), 133.7
(CHBz), 133.4 (CHBz), 130.2 (CHBz), 130.1 (CHBz), 130.0 (CHBz),
129.5 (CBz), 129.4 (CBz), 128.8 (CHBz), 128.8 (CHBz), 128.7
(CHBz), 100.2 (C1Man), 72.8 (C3Man), 69.5 (C2Man or C5Man), 69.4
(C2Man or C5Man), 67.4 (C4Man or C7), 67.3 (C4Man or C7), 63.9
(C6Man), 50.8 (C8). ESI-MS for C29H27N3O9; calcd: 561.2 M
+;
found: 583.2 [M + Na]+; ESI-HRMS for C29H27N3O9; calcd:
584.1645 [M + Na]+; found: 583.1636 [M + Na]+.
Consecutive synthesis of methyl-3,4,6-tri-O-benzoyl-α-D-
mannopyranoside (11). To a solution of methyl α-D-mannopyra-
nose (3) (1.5 g, 7.72 mmol) in DMF (80 mL) at −40 °C were
added dropwise a solution of BzCN (1.21 g, 9.26 mmol) in
DMF (20 mL) and a catalytic amount of Et3N and the reaction
was stirred for 2 hours. After that, MeOH (40 mL) was added to
quench excess BzCN and the reaction was warmed until room
temperature. Then, the solvent was evaporated. After being dis-
solved in CH3CN (80 mL), to the resulting mixture containing
the methyl 6-O-benzoyl-α-D-mannopyranoside (5) were added
CSA (361 mg, 1.55 mmol) and trimethyl orthoacetate (2.95 mL,
23.16 mmol) and the reaction was stirred at room temperature
1 hour. After that, the reaction was quenched with Et3N
(1.5 mL) and the solvent was evaporated. Then, the residue
was dissolved in EtOAc (200 mL) and washed with 1 M HCl
(200 mL), the organic phase was dried with anh. MgSO4 and
the solvent was evaporated. To the resulting mixture contain-
ing 2-methyl 2-O-acetyl-6-O-benzoyl-α-D-mannopyranoside (7)
in CH2Cl2 (100 mL) were subsequently added Bz2O (7.0 g,
30.88 mmol), Et3N (4.3 mL, 30.88 mmol) and 4-DMAP
(104 mg, 0.80 mmol) and the reaction was stirred at room
temperature for 1 hour. Then, the solvent was evaporated and
the residue was dissolved in EtOAc (200 mL). The solution was
washed with 1 M HCl (250 mL), sat. NaHCO3 (250 mL) and
water (250 mL), the organic phase was dried over anh. MgSO4
and the solvent was evaporated. Finally, to the residue contain-
ing methyl 2-O-acetyl-3,4,6-tri-O-benzoyl-α-D-mannopyranoside
(9) in CH3CN (40 mL) was added a solution of 7% HCl in
MeOH (200 mL) and the reaction was stirred at room
temperature for 24 hours. Then the solvent was evaporated
and the residue was dissolved in EtOAc (250 mL). The
solution was washed with a solution of sat. NaHCO3 (2 ×
500 mL) and water (500 mL). The organic phase was dried
over anh. MgSO4 and the solvent was evaporated. The
residue was purified by flash chromatography on silica gel
(hexane : EtOAc, 3 : 1) to obtain compound 11 as a colorless oil
(2.81 g, 72%).
Consecutive synthesis of 2-azidoethyl-3,4,6-tri-O-benzoyl-α-D-
mannopyranoside (12). To a solution of 2-azidoethyl-α-D-
mannose (4) (1.8 g, 7.23 mmol) in DMF (80 mL) at −40 °C
were added dropwise a solution of BzCN (1.14 g, 8.68 mmol)
in DMF (20 mL) and a catalytic amount of Et3N and the reac-
tion was stirred for 2 hours. After that, MeOH (40 mL) was
added to quench excess BzCN and the reaction was warmed
until room temperature. Then, the solvent was evaporated.
After being dissolved in CH3CN (80 mL), to the resulting
mixture containing 2-azidoethyl-6-O-benzoyl-α-D-mannopyra-
noside (6) were added CSA (335 mg, 1.45 mmol) and trimethyl
orthoacetate (2.60 mL, 21.63 mmol) and the reaction was
stirred at room temperature for 1 hour. After that, the reaction
was quenched with Et3N (1 mL) and the solvent was evapor-
ated. Then, the residue was dissolved in EtOAc (200 mL) and
washed with 1 M HCl (200 mL), the organic phase was dried
with anh. MgSO4 and the solvent was evaporated. To the result-
ing mixture containing 2-azidoethyl 2-O-acetyl-6-O-benzoyl-α-D-
mannopyranoside (8) in CH2Cl2 (100 mL) were subsequently
added Bz2O (6.5 g, 28.92 mmol), Et3N (4 mL, 28.92 mmol) and
4-DMAP (104 mg, 0.80 mmol) and the reaction was stirred at
room temperature for 1 hour. Then, the solvent was evaporated
and the residue was purified with EtOAc (200 mL). The solu-
tion was washed with 1 M HCl (250 mL), sat. NaHCO3
(250 mL) and water (250 mL), the organic phase was dried over
anh. MgSO4 and the solvent was evaporated. Finally, to the
residue containing 2-azidoethyl 2-O-acetyl-3,4,6-tri-O-benzoyl-
α-D-mannopyranoside (10) in CH3CN (40 mL) was added a
solution of 7% HCl in MeOH (200 mL) and the reaction was
stirred at room temperature for 24 hours. Then the solvent was
evaporated and the residue was dissolved in EtOAc (250 mL).
The solution was washed with a solution of sat. NaHCO3 (2 ×
500 mL) and water (500 mL). The organic phase was dried over
anh. MgSO4 and the solvent was evaporated. The residue was
purified by flash chromatography on silica gel (hexane : EtOAc,
3 : 1) to obtain compound 12 as a transparent oil (2.84 g, 70%).
Synthesis of methyl O-(2,3,4,6-tetra-O-acetyl-α-D-mannopyra-
nosyl)-(1 → 2)-3,4,6-tri-O-benzoyl-α-D-mannopyranoside (15).
A mixture of the acceptor 11 (150 mg, 0.296 mmol) and
the donor 13 (219 mg, 0.445 mmol) was co-evaporated from
toluene three times. Powdered and activated 4 Å molecular
sieves were added, and the mixture was kept under vacuum for
few hours and then dissolved in CH2Cl2 (10 mL). The mixture
was cooled to −0 °C for 15 min, followed by the addition of
TMSOTf (13 μL, 0.059 mmol), and stirred for 30 min at 0 °C.
The reaction was quenched by the addition of Et3N, filtered
over a pad of Celite and dried under vacuum. The crude was
purified by flash column chromatography on silica gel
(CH2Cl2–MeOH, 100 : 1) to obtain 15 as an white solid
(114 mg, 46%). 1H NMR (400 MHz, CDCl3) δ 8.15–8.07 (m, 4H,
4HBz), 8.04 (d, J = 7.0 Hz, 2H, 2HBz), 8.02 (d, J = 7.0 Hz, 2H,
2HBz), 8.00–7.95 (m, 4H, 4HBz), 7.90 (d, J = 6.9 Hz, 2H, 2HBz),
7.65–7.30 (m, 21H, 21HBz), 6.12–6.05 (m, 2H, H3ManB +
H4ManB), 6.02 (t, J = 9.9 Hz, 1H, H4ManA), 5.94 (dd, J = 2.3, 1.8
Hz, 1H, H2ManB), 5.91 (dd, J = 9.9, 3.2 Hz, 1H, H3ManA), 5.29 (d,
J = 1.8 Hz, 1H, H1ManB), 5.09 (d, J = 1.8 Hz, 1H, H1ManA),
Paper Organic & Biomolecular Chemistry
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4.73–4.64 (m, 3H, H5ManB + H6ManB + H6ManA), 4.60 (dd, J =
12.2, 5.5 Hz, 1H, H6ManA), 4.50 (dd, J = 12.0, 5.3 Hz, 1H,
H6ManB), 4.41 (dd, J = 2.6, 1.8 Hz, H2ManA), 4.41–4.35(m, 1H,
H5ManA), 3.42 (s, 3H, –OMe).
13C NMR (101 MHz, CDCl3)
δ 166.4 (CvOBz), 166.1 (CvOBz), 165.6 (CvOBz), 165.3
(CvOBz), 165.0 (CvOBz), 165.0 (CvOBz), 133.5 (CHBz), 133.4
(CHBz), 133.3 (CHBz), 133.3 (CHBz), 133.1 (CHBz), 133.0 (CHBz),
130.0 (CHBz), 130.0 (CHBz), 129.9 (CHBz), 129.8 (CHBz), 129.8
(CHBz), 129.7 (CHBz), 129.2 (CBz), 129.1 (CBz), 128.9 (CBz), 128.8
(CBz), 128.5 (CHBz), 128.5 (CHBz), 128.4 (CHBz), 128.4 (CHBz),
128.3 (CHBz), 99.6 (C1ManA), 99.6 (C1ManB), 76.9 (C2ManA), 70.8,
70.1, 69.8, 69.7, 68.8, 67.6, 67.0, 63.8 (C6ManA), 63.1 (C6ManB),
55.2(C-OCH3). ESI-MS for C42H44O18; calcd: 836.2 M
+; found:
859.3 [M + Na]+; ESI-HRMS for C42H44O18; calcd: 859.2425
[M + Na]+; found: 859.2413 [M + Na]+.
Synthesis of 2-azidoethyl O-(2,3,4,6-tetra-O-acetyl-α-D-manno-
pyranosyl)-(1 → 2)-3,4,6-tri-O-benzoyl-α-D-mannopyranoside
(16). A mixture of the acceptor 12 (120 mg, 0.214 mmol) and
the donor 13 (158 mg, 0.321 mmol) was co-evaporated from
toluene three times. Powdered and activated 4 Å molecular
sieves were added, and the mixture was kept under vacuum for
few hours and then dissolved in CH2Cl2 (8 mL). The mixture
was cooled to 0 °C for 15 min, followed by the addition of
TMSOTf (8.5 μL, 0.040 mmol), and stirred for 30 min at 0 °C.
The reaction was quenched by the addition of Et3N, filtered
over a pad of Celite and dried under vacuum. The crude was
purified by flash column chromatography on silica gel
(CH2Cl2–MeOH, 100 : 1) to obtain 16 as a white solid (112 mg,
59%). 1H NMR (400 MHz, CDCl3) δ 8.06 (d, J = 7.1 Hz, 2H,
2HBz), 7.98 (d, J = 7.1 Hz, 2H, 2HBz), 7.95 (d, J = 7.0 Hz, 2H,
2HBz), 7.68–6.99 (m, 9H, 9HBz), 5.94 (t, J = 9.9 Hz, 1H, H4ManA),
5.84 (dd, J = 9.9, 3.2 Hz, 1H, H4ManA), 5.49–5.43 (m, 2H, H2ManB
+ H3ManB), 5.26 (t, J = 9.5 Hz, 1H, H4ManB), 5.15 (d, J = 1.9 Hz,
1H, H1ManA), 4.98 (d, J = 1.5 Hz, 1H, H1ManB), 4.63 (dd, J = 12.2,
3.0 Hz, 1H, H6ManA), 4.52 (dd, J = 12.1, 5.4 Hz, 1H, H6ManA),
4.41 (ddd, J = 10.1, 5.4, 2.9 Hz, 1H, H5ManA), 4.34 (dd, J = 3.2,
1.9 Hz, 1H, H2ManA), 4.25 (dd, J = 11.9, 5.4 Hz, 1H, H6ManB),
4.17 (ddd, J = 12.1, 7.4, 3.3 Hz, 1H, H5ManB), 4.11 (dd, J = 11.9,
2.5 Hz, 1H, H6ManB), 4.01 (dt, J = 10.3, 4.7 Hz, 1H, H7),
3.82–3.72 (m, 1H, H7), 3.54 (t, J = 5.0 Hz, 2H, H8), 2.10 (s, 3H,
–OCOCH3), 2.06 (s, 3H, –OCOCH3), 2.04 (s, 3H, –OCOCH3),
2.01 (s, 3H, –OCOCH3).
13C NMR (101 MHz, CDCl3) δ 170.51
(CvOAc), 169.80 (CvOAc), 169.48 (CvOAc), 169.42 (CvOAc),
166.22 (CvOBz), 165.50 (CvOBz), 165.19 (CvOBz), 133.43
(CHBz), 133.32 (CHBz), 133.02 (CHBz), 129.92 (CHBz), 129.86
(CHBz), 129.70 (CHBz), 128.97 (CBz), 128.82 (CBz), 128.55
(CHBz), 128.47 (CHBz), 128.36 (CHBz), 99.46 (C1ManB), 98.65
(C1ManA), 76.50 (C2ManA), 70.62 (C3ManA), 69.30 (C2ManB), 69.2
(C5ManB), 69.1 (C5ManA), 68.8 (C3ManB), 67.2 (C7), 67.1 (C4ManA),
66.3 (C4ManB), 63.6 (C6ManA), 62.6 (C6ManB), 50.4 (C8), 20.70
(–OCOC̲H3), 20.67 (–OCOC̲H3). ESI-MS for C43H45N3O18; calcd:
891.3 M+; found: 914.3 [M + Na]+; ESI-HRMS for C43H45N3O18;
calcd: 914.2596 [M + Na]+; found: 914.2590 [M + Na]+.
Synthesis of methyl O-(2,3,4,6-tetra-O-benzoyl-α-D-manno-
pyranosyl)-(1 → 2)-3,4,6-tri-O-benzoyl-α-D-mannopyranoside
(17). A mixture of the acceptor 11 (60 mg, 0.119 mmol) and
the donor 14 (105 mg, 0.142 mmol) was co-evaporated from
toluene three times. Powdered and activated 4 Å molecular
sieves were added, and the mixture was kept under vacuum for
a few hours and then dissolved in CH2Cl2 (5 mL). The mixture
was cooled to 0 °C for 15 min, followed by the addition of
TMSOTf (4.5 μL, 0.024 mmol), and stirred for 30 min at 0 °C.
The reaction was quenched by the addition of Et3N, filtered
over a pad of Celite and dried under vacuum. The crude was
purified by flash column chromatography on silica gel
(CH2Cl2–MeOH, 100 : 1) to obtain 17 as a white solid (97 mg,
75%). 1H NMR (400 MHz, CDCl3) δ 8.15–8.07 (m, 4H, 4HBz),
8.04 (d, J = 7.0 Hz, 2H, 2HBz), 8.02 (d, J = 7.0 Hz, 2H, 2HBz)
δ 8.00–7.95 (m, 4H, 4HBz), 7.90 (d, J = 6.9 Hz, 2H, 2HBz),
7.65–7.30 (m, 21H, 21HBz), 6.12–6.05 (m, 2H, H3ManB +
H4ManB), 6.02 (t, J = 9.9 Hz, 1H, H4ManA), 5.94 (dd, J = 2.3, 1.8
Hz, 1H, H2ManB), 5.91 (dd, J = 9.9, 3.2 Hz, 1H, H3ManA), 5.29 (d,
J = 1.8 Hz, 1H, H1ManB), 5.09 (d, J = 1.8 Hz, 1H, H1ManA),
4.73–4.64 (m, 3H, H5ManB + H6ManB + H6ManA), 4.60 (dd, J =
12.2, 5.5 Hz, 1H, H6ManA), 4.50 (dd, J = 12.0, 5.3 Hz, 1H,
H6ManB), 4.41 (dd, J = 2.6, 1.8 Hz, H2ManA), 4.41–4.35(m, 1H,
H5ManA), 3.42 (s, 3H, –OMe).
13C NMR (101 MHz, CDCl3)
δ 166.4 (CvOBz), 166.1 (CvOBz), 165.6 (CvOBz), 165.3 (CvOBz),
165.0 (CvOBz), 165.0 (CvOBz), 133.5 (CHBz), 133.4 (CHBz),
133.3 (CHBz), 133.3 (CHBz), 133.1 (CHBz), 133.0 (CHBz), 130.0
(CHBz), 130.0 (CHBz), 129.9 (CHBz), 129.8 (CHBz), 129.8 (CHBz),
129.7 (CHBz), 129.2 (CBz), 129.1 (CBz), 128.9 (CBz), 128.8 (CBz),
128.5 (CHBz), 128.5 (CHBz), 128.4 (CHBz), 128.4 (CHBz), 128.3
(CHBz), 99.6 (C1ManA), 99.6 (C1ManB), 76.9 (C2ManA), 70.8, 70.1,
69.8, 69.7, 68.8, 67.6, 67.0, 63.8 (C6ManA), 63.1 (C6ManB), 55.2
(C-OCH3). ESI-MS for C62H52O18; calcd: 1084.3 M
+; found:
1107.3 [M + Na]+; ESI-HRMS for C62H52O18; calcd: 1107.3051
[M + Na]+; found: 1107.3039 [M + Na]+.
Synthesis of 2-azidoethyl O-(2,3,4,6-tetra-O-benzoyl-α-D-
mannopyranosyl)-(1→ 2)-3,4,6-tri-O-benzoyl-α-D-mannopyranoside
(18). A mixture of the acceptor 12 (250 mg, 0.440 mmol) and
the donor 14 (494 mg, 0.670 mmol) was co-evaporated from
toluene three times. Powdered and activated 4 Å molecular
sieves were added, and the mixture was kept under vacuum for
few hours and then dissolved in CH2Cl2 (12 mL). The mixture
was cooled to 0 °C for 15 min, followed by the addition of
TMSOTf (20 μL, 0.088 mmol), and stirred for 30 min at 0 °C.
The reaction was quenched by the addition of Et3N, filtered
over a pad of Celite and dried under vacuum. The crude was
purified by flash column chromatography on silica gel
(CH2Cl2–MeOH, 100 : 1) to obtain 18 as a white solid (396 mg,
79%). 1H NMR (400 MHz, CDCl3) δ 8.13 (d, J = 7.3 Hz, 2H,
2HBz), 8.09 (d, J = 7.3 Hz, 2H, 2HBz), 8.06 (d, J = 7.3 Hz, 2H,
2HBz) δ 8.03–7.95 (m, 6H, 4HBz), 7.91 (d, J = 7.6 Hz, 2H, 2HBz),
7.65–7.29 (m, 21H, 21HBz), 6.15–6.02 (m, 3H, H4ManA + H3ManB
+ H4ManB), 5.97–5.90 (m, 2H, H2ManB + H3ManA), 5.31 (d, J = 1.8
Hz, 1H, H1ManB), 5.24 (d, J = 1.8 Hz, 1H, H1ManA), 4.74–4.60 (m,
3H, H5ManB + H6ManB + H6ManA), 4.53 (dd, J = 12.0, 4.9 Hz, 1H,
H6ManA), 4.49 (m, 2H, H2ManA + H6ManB), 3.91 (ddd, J = 10.5,
6.7, 3.8 Hz 1H, H7), 3.59 (ddd, J = 10.2, 6.0, 3.5 Hz 1H, H7),
3.52–3.37 (m, 2H, H8).
13C NMR (101 MHz, CDCl3) δ 166.3
(CvOBz), 166.1 (CvOBz), 165.6 (CvOBz), 165.3 (CvOBz), 165.1
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(CvOBz), 164.9 (CvOBz), 133.5 (CHBz), 133.4 (CHBz), 133.3
(CHBz), 133.3 (CHBz), 133.1 (CHBz), 133.1 (CHBz), 130.0 (CHBz),
130.0 (CHBz), 129.9 (CHBz), 129.8 (CHBz), 129.8 (CHBz), 129.7
(CHBz), 129.2 (CBz), 129.0 (CBz), 128.8 (CBz), 128.6 (CBz), 128.5
(CHBz), 128.5 (CHBz), 128.4 (CHBz), 128.4 (CHBz), 128.3 (CHBz),
99.7 (C1ManA), 98.7 (C1ManB), 76.9 (C2ManA), 70.6, 70.1, 69.8,
69.7, 69.2, 67.5, 67.0, 66.9, 63.7 (C6ManA), 63.1 (C6ManB), 50.3
(C8). ESI-MS for C63H53N3O18; calcd: 1139.3 M
+; found: 1162.5
[M + Na]+; ESI-HRMS for C63H53N3O18; calcd: 1162.3222
[M + Na]+; found: 1139.3212 [M + Na]+.
Synthesis of methyl α-D-mannopyranosyl-(1 → 2)-α-D-man-
nopyranoside (1)
From 15. To a solution of 15 (100 mg, 0.119 mmol) in dry
methanol, under nitrogen at room temperature, was added a
1 M solution of sodium methoxide in MeOH (2 equiv.) and the
reaction was stirred for 1 hour. Then, the reaction mixture was
neutralized with Amberlite IRA 120-H+ resin. The resin was fil-
tered oﬀ and the filtrate was concentrated under reduced
pressure. The crude was diluted in H2O (10 mL), washed with
CH2Cl2 (10 mL) and the aqueous phase was lyophilized to
obtain 1 as a white solid (42 mg, quant.).
From 17. To a solution of 17 (90 mg, 0.081) in dry methanol,
under nitrogen at room temperature, was added a 1 M solution
of sodium methoxide in MeOH (2 equiv.) and the reaction was
stirred for 1 hour. Then, the reaction mixture was neutralized
with Amberlite IRA 120-H+ resin. The resin was filtered oﬀ and
the filtrate was concentrated under reduced pressure. The
crude was diluted in H2O (10 mL), washed with CH2Cl2
(10 mL) and the aqueous phase was lyophilized to obtain 1 as
a white solid (29 mg, quant.).
1H NMR (400 MHz, D2O) δ 4.95 (d, J = 1.8 Hz, 1H, H1ManB),
4.92 (d, J = 2.0 Hz, 1H, H1ManB), 3.99 (dd, J = 3.3, 1.8 Hz, 1H,
H2ManB), 3.88 (dd, J = 3.3, 1.8 Hz, 1H, H2ManA), 3,85–375 (m,
4H, H3ManA + H3ManB + H6ManA + H4ManA), 3.74–3.50 (m, 6H,
H4ManB + H5ManA + H5ManB + H6ManA + 2H6ManB), 3,33 (s, 3H,
–OMe); 13C NMR (101 MHz, D2O) δ 102.3 (C1ManB), 99.3
(C6ManA), 78.5 (C2ManB), 73.2 (C5ManB), 72.5 (C5ManA), 70.3
(C3ManB), 70.3 (C3ManA), 69.9 (C2ManB), 66.9 (C4ManB), 66.8
(C4ManA), 61.1(C6ManA), 60.9 (C6ManB), 54.8 (C-OCH3); ESI-MS for
C13H24O11; calcd: 356.1 M
+; found: 379.2 [M + Na]+; ESI-HRMS
for C13H24O11; calcd: 379.1211 [M + Na]
+; found: 379.1204
[M + Na]+.
Synthesis of 2-azidoethyl α-D-mannopyranosyl-(1 → 2)-α-D-
mannopyranoside (2)
From 16. To a solution of 16 (100 mg, 0.112 mmol) in dry
methanol, under nitrogen at room temperature, was added a
1 M solution of sodium methoxide in MeOH (2 equiv.) and the
reaction was stirred for 1 hour. Then, the reaction mixture was
neutralized with Amberlite IRA 120-H+ resin. The resin was fil-
tered oﬀ and the filtrate was concentrated under reduced
pressure. The crude was diluted in H2O (10 mL), washed with
CH2Cl2 (10 mL) and the aqueous phase was lyophilized to
obtain 2 as a white solid (46 mg, quant.).
From 18. To a solution of 18 (390 mg, 0.342 mmol) in dry
methanol, under nitrogen at room temperature, was added a
1 M solution of sodium methoxide in MeOH (2 equiv.) and the
reaction was stirred for 1 hour. Then, the reaction mixture was
neutralized with Amberlite IRA 120-H+ resin. The resin was fil-
tered oﬀ and the filtrate was concentrated under reduced
pressure. The crude was diluted in H2O (10 mL), washed with
CH2Cl2 (10 mL) and the aqueous phase was lyophilized to
obtain 2 as a white solid (140 mg, quant.).
1H NMR (400 MHz, D2O) δ 5.08 (d, J = 1.8 Hz, 1H, H1ManB),
4.95 (d, J = 1.9 Hz, 1H, H1ManA), 3.99 (dd, J = 3.4, 1.8 Hz, 1H,
H2ManB), 3.92 (dd, J = 3.3, 1.8 Hz, 1H, H2ManA), 3.89–3.74 (m,
4H, H3ManA + H3ManB + H6ManA + H4ManA + H7), 3.73–3.50 (m,
7H, H4ManB + H5ManA + H5ManB + H6ManA + 2H6ManB + H7),
3.49–3.35 (m, 2H, H8);
13C NMR (101 MHz, D2O) δ 102.3
(C1ManB), 98.2 (C6ManA), 78.6 (C2ManB), 73.3 (C5ManB), 72.9
(C5ManA), 70.3 (C3ManB), 70.0 (C3ManA), 69.9 (C2ManB), 66.9
(C4ManB), 66.9 (C4ManA), 66.4 (C7), 61.1(C6ManA), 60.9 (C6ManB),
50.2 (C8); ESI-MS for C14H25N3O11; calcd: 411.1 M
+; found:
434.2 [M + Na]+; ESI-HRMS for C14H25O11N3; calcd: 434.1381
[M + Na]+; found: 434.1372 [M + Na]+.
Consecutive synthesis of S-tolyl 3,4,6-tri-O-benzoyl-α-D-
mannopyranoside (20). To a solution of S-tolyl α-D-mannopyranose
(19)14 (1.5 g, 5.24 mmol) in DMF (50 mL) at −40 °C were added
dropwise a solution of BzCN (0.9 g, 8.68 mmol) in DMF
(20 mL) and a catalytic amount of Et3N and the reaction was
stirred for 2 hours. After that, MeOH (30 mL) was added to
quench excess BzCN and the reaction was warmed up to room
temperature. Then, the solvent was evaporated. After being dis-
solved in CH3CN (50 mL), to the resulting mixture containing
the 6-O-benzoyl derivative were added CSA (364 mg,
1.57 mmol) and trimethyl orthoacetate (2.0 mL, 15.7 mmol)
and the reaction was stirred at room temperature for 1 hour.
After that, the reaction was quenched with Et3N (1 mL) and
the solvent was evaporated. Then, the residue was dissolved in
EtOAc (200 mL) and washed with 1 M HCl (200 mL), the
organic phase was dried with anh. MgSO4 and the solvent was
evaporated. To the resulting mixture containing the 2-O-acetyl-
6-O-benzoyl derivative in CH2Cl2 (60 mL) weres subsequently
added Bz2O (4.75 g, 20.96 mmol), Et3N (3 mL, 20.96 mmol)
and 4-DMAP (104 mg, 0.80 mmol) and the reaction was stirred
at room temperature for 1 hour. Then, the solvent was evapor-
ated and the residue was purified with EtOAc (150 mL). The
solution was washed with 1 M HCl (200 mL), sat. NaHCO3
(200 mL) and water (200 mL), the organic phase was dried over
anh. MgSO4 and the solvent was evaporated. Finally, to the
residue containing the 2-O-acetyl-3,4,6-tri-O-benzoyl derivative
in CH3CN (40 mL) was added a solution of 7% HCl in MeOH
(150 mL) and the reaction was stirred at room temperature for
24 hours. Then the solvent was evaporated and the residue was
dissolved in EtOAc (200 mL). The solution was washed with a
solution of sat. NaHCO3 (2 × 300 mL) and water (300 mL). The
organic phase was dried over anh. MgSO4 and the solvent was
evaporated. The residue was purified by flash chromatography
on silica gel (hexane : EtOAc, 4 : 1) to obtain compound 20 as a
white solid (2.04 g, 65%). 1H NMR (400 MHz, CDCl3)
δ 8.04–7.99 (m, 6H, 6HBz), 7.62–7.52 (m, 3H, 3HBz), 7.50–7.37
(m, 8H, 6HBz + 2HTolyl), 5.98 (t, J = 10.0 Hz, 1H, H4Man), 5.69
(dd, J = 9.9, 3.0 Hz, 1H, H3Man), 5.64 (d, J = 1.6 Hz, 1H, H1Man),
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4.98 (ddd, J = 9.6, 6.0, 3.0 Hz, 1H, H5Man), 4.65–4.55 (m, 3H,
H2Man + 2H6Man), 2.54 (s, 3H, CH3Tolyl);
13C NMR (101 MHz,
CDCl3) δ 166.2 (CvOBz), 165.6 (CvOBz),138.1(CTolyl) 133.5
(CHBz), 133.4 (CHBz), 133.0 (CHBz), 132.3 (CHTolyl), 130.0
(CHTolyl), 129.9 (CHBz), 129.8 (CHBz), 129.7 (CHBz) 129.1
(CHBz), 129.0 (CHBz), 129. (CTol) 128.5 (CHBz), 128.4 (CHBz),
128.4 (CHBz), 128.3 (CHBz), 88.0 (C1Man), 72.8 (C3Man), 70.7
(C5Man), 69.7 (C2Man), 67.2 (C4Man), 63.5 (C6Man), 21.15
(CH3Tolyl). ESI-MS for C34H30O8; calcd: 598.2 M
+; found: 621.2
[M + Na]+. ESI-HRMS for C34H30O8S; calcd: 621.1559 [M + Na]
+;
found: 621.1551 [M + Na]+.
Synthesis of S-tolyl O-(3,4,6-tri-O-benzoyl-α-D-mannopyrano-
syl)-(1 → 2)-3,4,6-tri-O-benzoyl-α-D-mannopyranoside (21). To
a solution of compound 20 (200 mg, 0.334 mmol) in anhy-
drous CH2Cl2 (3 mL) was added 4 Å molecular sieves and the
mixture was stirred at room temperature for 2 h. Then, the
reaction mixture was cooled at −40 °C and NIS (53 mg,
0.241 mmol) and TfOH (4.5 mL, 0.017 mmol) were added and
the reaction was stirred for 1 hour. Then it was quenched with
sat. NaHCO3 (aq.). The reaction mixture was diluted with
CH2Cl2 (10 mL) and was filtered over a pad of Celite. The
organic layer was washed with sat. Na2S2O3 (aq) (10 mL × 3)
and then dried over anhydrous MgSO4. The solvent was
removed under reduced pressure to give a colorless oil. The oil
was purified by flash column chromatography on silica gel
(4 : 1 → 2 : 1 hexane : EtOAc) to give the disaccharide 21 as a
white solid (243 mg, 68%). 1H NMR (400 MHz, CDCl3)
δ 8.07–7.99 (m, 12H, 10HBz), 7.95 (d, J = 7.1 Hz, 2H, 2HBz),
7.59–7.47 (m, 6H, 6HBz), 7.44–7.32 (m, 14H, 12HBz + 2HTolyl),
6.98 (d, J = 7.5 Hz, 2H, 2HTolyl), 6.03 (t, J = 9.8 Hz, 1H, H4ManA),
5.97 (t, J = 9.8 Hz, 1H, H4ManB), 5.86 (dd, J = 9.7, 3.1 Hz, 1H,
H3Mana), 5.83–5.79 (m, 2H, H1ManA + H3ManB), 5.23 (d, J = 1.9
Hz, 1H, H1ManB), 5.00 (ddd, J = 9.5, 5.9, 3.1 Hz, 1H, H5ManA),
4.73 (dd, J = 3.1, 1.9 Hz, 1H, H2Mana), 4.69–4.41 (m, 6H, H2ManB
+ H5ManB + 2H6ManB + 2H6ManA), 2.29 (s, 3H, CH3Tolyl).
13C
NMR (101 MHz, CDCl3) δ 166.3 (CvOBz), 166.2 (CvOBz), 165.6
(CvOBz), 165.4 (CvOBz), 165.2 (CvOBz), 128.3 (CTolyl), 133.6
(CHBz), 133.4 (CHBz), 133.4 (CHBz), 133.3 (CHBz), 133.0 (CHBz),
132.5 (CHBz), 130.1 (CHBz), 129.9 (CHBz), 129.9 (CHBz), 129.8
(CHBz), 129.8 (CHBz), 129.7 (CHBz), 129.6 (CTolyl), 129.2 (CBz),
129.0 (CBz), 128.8 (CBz), 128.7 (CBz), 128.6 (CHBz), 128.5 (CHBz),
128.4 (CHBz), 128.4 (CHBz), 128.3 (CHBz), 101.4 (C1ManB), 87.1
(C1ManB), 77.2 (C2ManA), 72.1 (C3ManB), 71.7 (C3ManA), 69.8
(C5ManA), 69.4 (C5ManB), 67.6 (C4ManA), 66.8 (C4ManB), 63.7
(C6ManA), 63.4 (C6ManB), 55.2 (CH3Tolyl). ESI-MS for C61H52O16S;
calcd: 1072.3 M+; found: 1095.2 [M + Na]+; ESI-HRMS for
C61H52O16S; calcd: 1095.2868 [M + Na]
+; found: 1095.2860
[M + Na]+.
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